Home・Aktien・Geron Corp

Geron Corp

Open

BrancheGesundheitswesen

1.61 20.15

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.34

Max

1.6099999999999999

Schlüsselkennzahlen
By Trading Economics
Einkommen	25M -3.6M
Verkäufe	3.8M 52M
EPS	-0.005
Gewinnspanne	-7.026
Angestellte	258
EBITDA	27M 3.8M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+198.51% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-185M 821M
Vorheriger Eröffnungskurs	-18.54
Vorheriger Schlusskurs	1.61

Nachrichtenstimmung

By Acuity

20%

80%

55 / 340 Ranking in Healthcare

Geron Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Aug. 2026, 23:36 UTC

Geron Corp shares are lower in after-market trading, nearing the bottom of their one-month range and below the 20-day moving average.

3. Aug. 2026, 23:06 UTC

Geron Corp shares are lower in after-market hours, continuing a steady decline since Monday's close and remaining below the 20-day moving average.

31. Juli 2026, 20:02 UTC

Geron Corp shares are lower as the Biotechnology sub-sector declines. The stock pulled back from an earlier session high, finishing below its 20-day moving average.

30. Juli 2026, 20:56 UTC

Geron Corp shares are higher in after-market hours, influenced by positive corporate earnings amid broader market uncertainty following the Federal Reserve's interest rate decision.

29. Juli 2026, 19:32 UTC

Macro Event

Geron Corp shares are lower as market volatility rises following the Federal Reserve's interest rate decision amid ongoing economic growth and inflation concerns.

28. Juli 2026, 18:51 UTC

Shares of Geron Corp are lower today amid broader market volatility and uncertainty regarding Federal Reserve decisions. The stock declined since Monday's close.

27. Juli 2026, 23:16 UTC

Geron Corp shares are lower in after-market trading, despite earlier gains, with no specific company news driving the decline.

24. Juli 2026, 19:46 UTC

Geron Corp shares are lower in Friday's session amid broader market volatility and uncertainty from fluctuating oil prices and new U.S. tariffs.

23. Juli 2026, 10:11 UTC

Shares of Geron Corp are higher in pre-market hours, trading above their 20-day moving average. No specific company news was identified.

22. Juli 2026, 18:51 UTC

Geron Corp shares are lower today amid broader market trends, as crude oil prices surge due to geopolitical tensions.

21. Juli 2026, 23:41 UTC

Geron Corp shares are lower in after-market trading, declining to their lowest point since Tuesday's close. No specific news was identified to explain the drop.

20. Juli 2026, 23:56 UTC

Geron Corp shares are lower in after-market hours, continuing a decline since Monday's close amid broader market uncertainties and a drop in the leading economic index.

Peer-Vergleich

Kursveränderung

Geron Corp Prognose

Kursziel

By TipRanks

198.51% Vorteil

12-Monats-Prognose

Durchschnitt 4 USD 198.51%

Hoch 5 USD

Tief 3 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Geron Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Geron Corp – Dist abgegeben haben.

Stimmung

By Acuity

55 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.